The reduction of grain size to the nanometer range (˜2-100 nm) has led to many interesting materials properties, including those involving mechanical behavior. In the case of metals, the Hall-Petch equation, which relates the yield stress to the inverse square root of the grain size, predicts great increases in strength with grain refinement. On the other hand, theory indicates that the high volume fraction of interfacial regions leads to increased deformation by grain-boundary sliding in metals with grain size in the low end of the nanocrystalline range. Nanocrystalline ceramics also have desirable properties. Chief among these are lower sintering temperatures and enhanced strain to failure. These two properties acting in combination allow for some unique applications, such as low-temperature diffusion bonding (the direct joining of ceramics to each other using moderate temperatures and pressures). Mechanical properties sometimes are affected by the fact that ceramics in a fine-grained form are stable in a different (usually higher pressure) phase than that which is considered “normal” for the ceramic. To the extent that the mechanical properties of a ceramic are dependent on its crystal-lographic structure, these differences will become evident at the smaller size scales.It is uncertain how deformation takes place in very fine-grained nanocrystalline materials. It has been recognized for some time that the Hall-Petch relationship, which usually is explained on the basis of dislocation pileups at grain boundaries, must break down at grain sizes such that a grain cannot support a pileup. Even some of the basic assumptions of dislocation theory may no longer be appropriate in this size regime. Recently considerable progress has been made in simulating the behavior of extremely fine-grained metals under stress using molecular-dynamics techniques. Molecular-dynamics (MD) simulations of deformation in nanophase Ni and Cu were carried out in the temperature range of 300–500 K, at constant applied uniaxial tensile stresses between 0.05 GPa and 1.5 GPa, on samples with average grain sizes ranging from 3.4 nm to 12 nm.
BackgroundCirculating miRNAs are known to play important roles in intercellular communication. However, the effects of exosomal miRNAs on cells are not fully understood.MethodsTo investigate the role of exosomal miR-1246 in ovarian cancer (OC) microenvironment, we performed RPPA as well as many other in vitro functional assays in ovarian cancer cells (sensitive; HeyA8, Skov3ip1, A2780 and chemoresistant; HeyA8-MDR, Skov3-TR, A2780-CP20). Therapeutic effect of miR-1246 inhibitor treatment was tested in OC animal model. We showed the effect of OC exosomal miR-1246 uptake on macrophages by co-culture experiments.FindingsSubstantial expression of oncogenic miR-1246 OC exosomes was found. We showed that Cav1 gene, which is the direct target of miR-1246, is involved in the process of exosomal transfer. A significantly worse overall prognosis were found for OC patients with high miR-1246 and low Cav1 expression based on TCGA data. miR-1246 expression were significantly higher in paclitaxel-resistant OC exosomes than in their sensitive counterparts. Overexpression of Cav1 and anti-miR-1246 treatment significantly sensitized OC cells to paclitaxel. We showed that Cav1 and multi drug resistance (MDR) gene is involved in the process of exosomal transfer. Our proteomic approach also revealed that miR-1246 inhibits Cav1 and acts through PDGFβ receptor at the recipient cells to inhibit cell proliferation. miR-1246 inhibitor treatment in combination with chemotherapy led to reduced tumor burden in vivo. Finally, we demonstrated that when OC cells are co-cultured with macrophages, they are capable of transferring their oncogenic miR-1246 to M2-type macrophages, but not M0-type macrophages.InterpretationOur results suggest that cancer exosomes may contribute to oncogenesis by manipulating neighboring infiltrating immune cells. This study provide a new mechanistic therapeutic approach to overcome chemoresistance and tumor progression through exosomal miR-1246 in OC patients.
Cancer cells actively promote their tumorigenic behavior by reprogramming gene expression. Loading intraluminal vesicles with specific miRNAs and releasing them into the tumor microenvironment as exosomes is one mechanism of reprogramming whose regulation remains to be elucidated. Here, we report that miR-6126 is ubiquitously released in high abundance from both chemosensitive and chemoresistant ovarian cancer cells via exosomes. Overexpression of miR-6126 was confirmed in healthy ovarian tissue compared to ovarian cancer patient samples and correlated with better overall survival in high-grade serous ovarian cancer patients. miR-6126 acted as a tumor suppressor by directly targeting integrin β1, a key regulator of cancer cell metastasis. miR-6126 mimic treatment of cancer cells resulted in increased miR-6126 and decreased integrin β1 mRNA levels in the exosome. Functional analysis showed that treatment of endothelial cells with miR-6126 mimic significantly reduced tube formation as well as invasion and migration capacities of ovarian cancer cells in vitro. Administration of miR-6126 mimic in an orthotopic mouse model of ovarian cancer elicited a relative reduction in tumor growth, proliferating cells and microvessel density. miR-6126 inhibition promoted oncogenic behavior by leading ovarian cancer cells to release more exosomes. Our findings provide new insights into the role of exosomal miRNA-mediated tumor progression and suggest a new therapeutic approach to disrupt oncogenic phenotypes in tumors.
The need for high performance materials in aerospace, automotive and industrial components operating at temperatures in the range of 1100-1500uC has led to a surge in the research and development of the refractory metal silicide based intermetallics, multiphase alloys and composites. The silicides of Mo, W, Ti, Nb and Cr are attractive for high melting points, strength retention and ductile behaviour, combined with reasonable to excellent oxidation resistance at elevated temperatures. The major limitation to the widespread use of structural silicides is their inherent brittleness and poor fracture toughness at room temperature, which may be improved further by suitable alloying or tailoring composite microstructures or use of innovative processing routes. The high temperature deformation behaviour of the structural silicides is complex, and depends on the composition and alloy content, crystal structure, character of bonding and orientation, microstructural constitution (nature of phases present and volume fraction), and grain size. Over the past decade, the basic character and role of dislocations involved in the deformation of single or polycrystalline samples at different temperatures and strain rates, including creep conditions, have been investigated in order to understand the operating mechanisms and decide on the strategies to further improve the mechanical properties. Oxidation behaviour in different structural silicides has been studied with emphasis on the constitution of the oxide scale and the kinetics of oxidation under different temperature regimes, which also involve pest disintegration at intermediate temperatures. The present study is a review with a comparative assessment of the known mechanisms of deformation, fracture and oxidation along with strategies to improve the properties to the targeted levels and some of the emerging applications of structural silicides.
To address the need for efficient and biocompatible delivery systems for systemic siRNA delivery, we developed 1,2-Dioleoyl-sn-Glycero-3-Phosphatidylcholine (DOPC) nanoliposomal EphA2-targeted therapeutic (EPHARNA). Here, we performed safety studies of EPHARNA in murine and primate models. Single dosing of EPHARNA was tested at 5 concentrations in mice (N=15 per group) and groups were sacrificed on days 1, 14, and 28 for evaluation of clinical pathology and organ toxicity. Multiple dosing of EPHARNA was tested in mice and Rhesus macaques twice weekly at two dose levels in each model. Possible effects on hematologic parameters, serum chemistry, coagulation, and organ toxicity were assessed. Following single dose EPHARNA administration to mice, no gross pathological or dose-related microscopic findings were observed in either the acute (24 hrs) or recovery (14 and 28 days) phases. The no-observed-adverse-effect level (NOAEL) for EPHARNA is considered > 225 μg/kg when administered as a single injection intravenously in CD-1 mice. With twice weekly injection, EPHARNA appeared to stimulate a mild to moderate inflammatory response in a dose-related fashion. There appeared to be a mild hemolytic reaction in the female mice. In Rhesus macaques, minimal to moderate infiltration of mononuclear cells was found in some organs including the GI tract, heart, and kidney. No differences attributed to EPHARNA were observed. These results demonstrate that EPHARNA is well tolerated at all doses tested. These data, combined with previously published in vivo validation studies, have led to an ongoing first-in-human Phase I clinical trial (NCT01591356).
Despite substantial improvements in the treatment strategies, ovarian cancer is still the most lethal gynecological malignancy. Identification of drug treatable therapeutic targets and their safe and effective targeting is critical to improve patient survival in ovarian cancer. AXL receptor tyrosine kinase (RTK) has been proposed to be an important therapeutic target for metastatic and advanced-stage human ovarian cancer. We found that AXL-RTK expression is associated with significantly shorter patient survival based on the The Cancer Genome Atlas patient database. To target AXL-RTK, we developed a chemically modified serum nuclease-stable AXL aptamer (AXL-APTAMER), and we evaluated its in vitro and in vivo antitumor activity using in vitro assays as well as two intraperitoneal animal models. AXL-aptamer treatment inhibited the phosphorylation and the activity of AXL, impaired the migration and invasion ability of ovarian cancer cells, and led to the inhibition of tumor growth and number of intraperitoneal metastatic nodules, which was associated with the inhibition of AXL activity and angiogenesis in tumors. When combined with paclitaxel, in vivo systemic (intravenous [i.v.]) administration of AXL-aptamer treatment markedly enhanced the antitumor efficacy of paclitaxel in mice. Taken together, our data indicate that AXL-aptamers successfully target in vivo AXL-RTK and inhibit its AXL activity and tumor growth and progression, representing a promising strategy for the treatment of ovarian cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.